Table 1.

Baseline Characteristics of Patients with Severe COVID-19 Pneumonia.

		All patients (n=15)
Age, median (IQR)		59 (54-71)
Sex, n (%)
Male		12 (80.0)
BMI, kg/m2		27.1 (25.8-28.3)
Comorbidities, n (%)
Hypertension		12 (80.0)
Diabetes		9 (60.0)
Hyperlipidemia		6 (40.0)
Chronic kidney disease		2 (13.3)
Previous VTE		0 (0)
Anticoagulant therapy before admission, n (%)		0 (0)
COVID-19 vaccination, n (%)		1 (6.7)
Time of onset
The 3rd wave in Japan (2020.10-2021.2), n (%)		1 (6.7)
The 4th wave in Japan (2021.4-2021.5), n (%)		9 (60.0)
The 5th wave in Japan (2021.7-2021.9), n (%)		3 (20.0)
The 6th wave in Japan (2022.1-2022.3), n (%)		2 (13.3)
Intubation, n (%)		15 (100)
ECMO, n (%)		1 (6.7)
P/F ratio after intubation, median (IQR)		125 (98-153)
APACHE II score, median (IQR)		17 (13-30)
Pharmacological treatment for COVID-19
Remdesivir, n (%)		15 (100)
Dexamethasone, n (%)		15 (100)
Tocilizumab, n (%)		1 (6.7)
Baricitinib, n (%)		3 (20.0)
Unfractionated heparin, n (%)		15 (100)
At ICU discharge
Oxygen administration, n (%)		14 (93.3)
Steroid administration, n (%)		7 (46.7)
Antiplatelet administration, n (%)		3 (20.0)
Duration of mechanical ventilation (days), median (IQR)		9 (8-12)
ICU stay (days), median (IQR)		15 (12-18)
ICU mortality, n (%)		0 (0)
Hospital mortality, n (%)		0 (0)
Deep venous thrombosis, n (%)		1 (6.7)
Pulmonary embolism, n (%)		1 (6.7)
Other thromboembolic events, n (%)		0 (0)
Major bleeding, n (%)		0 (0)

COVID-19: coronavirus disease 2019, IQR: interquartile range, BMI: body mass index, VTE: venous thromboembolism, ECMO: extracorporeal membrane oxygenation, P/F: arterial partial pressure of oxygen/inspired oxygen concentration, APACHE-II: Acute Physiology and Chronic Health Evaluation-II, ICU: intensive care unit